compared eight oral antineoplastics (capecitabine, imatinib, lenalidomide, thalidomide, sunitinib, erlotinib, temozolomide, dasatinib) to a market basket of eight commonly utilized oral drugs (celecoxib, sitagliptin, rosuvastatin, fenofibrate, ramipril, simvastatin, atorvastatin, amlodipine). We calculated the correlation coefficient (r 2 ) for the relationships between a drug's average OPC and its TRx. RESULTS: Two of the eight cancer drugs (erlotinib and dasatinib) showed any remarkable correlations (r 2 0.17 and 0.29, respectively) while the other six all had correlation coefficients less than 0.10. Five of the market basket drugs had a correlation coefficient greater than 0.10. Four of those had negative correlations between OPC and TRx: simvastatin (r 2 0.71), sitagliptin (r 2 0.64), amlodipine (r 2 0.59), atorvastatin (r 2 0.14). Interestingly, ramipril had a significant positive correlation between OPC and TRx (r 2 0.51). CONCLUSIONS: Antineoplastic utilization appears to be inelastic with respect to OPC fluctuations vis-à-vis the chosen market basket. This observation may be a function of the severity of disease, the lack of treatment options or both. In contrast, changes in OPC for products in the general market basket, notably simvastin and sitagliptin, precipitated significant changes in drug utilization. Broader treatment options and specifically generic competition may contribute to this finding. Further research is warranted to track these relationships in a prospective, multi-factorial manner in order to better infer a cause-effect relationship.
PCN152 NEW JAPANESE PREFECTURAL GOVERNMENT CANCER CONTROL PROGRAMS: A SYSTEMATIC REVIEW AND AN INTERNATIONAL COMPARISON
Imai H 1 , Nakao H 1 , Sata F 1 , Fukuda Y 2 1 National Institute of Public Health, Wako-shi, Saitama, Japan, 2 Yamaguchi University, Ube, Yamaguchi, Japan OBJECTIVES: The Japanese Cancer Control Act took effect in 2007. The objectives of the Cancer Control Act are to improve regional cancer care and promote a uniformly high level of cancer care nationwide. To achieve these goals, the Act specifies that all 47 prefectural governments in Japan formulate cancer control programs (CCPs) by 2008. Our study aimed to systematically review the CCPs of 45 of Japan's prefectural governments that were formulated by January 2009 and then compare them to the programs that have been established in the West. METHODS: Six areas of the CCPs of 45 of Japan's prefectural governments were systematically reviewed: "prevention," "treatment," and "palliative care." etc. Parameters assessed included whether the proportion of smokers was being investigated, whether the numbers of radiation therapy and chemotherapy specialists engaged in cancer therapy were known, and whether the number of palliative care beds was known (a total of 224 parameters). RESULTS: The highest-rated plan overall received a score of 65.8, and the lowest a score of 35.3. Of the 45 plans, 21 (47%) established target values without actually determining the current proportion of minors who smoke, 25 (56%) did not investigate the numbers of specialists in cancer therapy. In addition, areas in which Japan is similar to the UK and the US, which operate CCPs on a national level, were clarified. CONCLUSIONS: It was found that not a few of the programs rest on shaky foundations and are of questionable implementability. An international comparison revealed that Britain's NHS Cancer Plan has achieved a reduction in the smoking rate and increased anticancer drug use, and the United States' NCCCP has produced results by supporting the CCPs of virtually all 50 states, achievements that should serve as a model for Japan. Cancer screening is essential component of national cancer control programmes. Screening programmes for breast, colorectal and cervical cancers are efficacious in decreasing cancer mortality and are recommended by the EU Council to all member states. For screening to be effective, delivery as organized programme is highly recommended. Vital part of organized programme is performance monitoring employing data on all screening tests performed. In absence of dedicated data collection system, alternative ways of performance monitoring should be employed. Our objective is to demonstrate feasibility of performance monitoring using administrative data. METHODS: This was a cross-sectional study to ascertain coverage by cancer screening tests in Czech population in years [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] . Administrative data from health insurance companies were collected by the National Reference Centre. Aggregated data were collected on procedures associated with cancer screening programmes, in particular screening mammography, FOBT, and gynaecology preventive examination. RESULTS: Most reliable data from years 2006-2007 were used for coverage estimation. In the two-year period, 745,725 women aged 45-69 years (43.5 %) underwent mammography screening, compared to 754,147 records in dedicated breast cancer screening database. In the same period, 593,512 men and women aged over 50 years (16.0 %) underwent colorectal cancer screening. In 2007, gynaecology preventive examination was attended by 1,083,256 women (40.9 % of population aged 25-59 years). CONCLUSIONS: Performance monitoring using administrative data is feasible, which was demonstrated by ascertaining screening test coverage. Concordance between administrative data and data in dedicated breast cancer screening database is excellent. Due to absence of actual data on population coverage in other screening programmes, administrative data is the only available and reliable source of information on access to programme by citizens in all regions. Future use of individual administrative data could help us to evaluate various other screening process components associated with its effectiveness, safety and cost-effectiveness. (trastuzumab, imatinib, docetaxel, oxaliplatin, rituximab and paclitaxel) accounted for 67% of TACDE. The number of patients receiving anticancer drugs and the number of dispensed drugs increased by 29,13% and 34,2%, respectively. Per patient anticancer drug expenditure increased from a3.896/patient in 2003 and a6.220/patient in 2007. Information in diagnosis was not available and analyses per type of cancer could not be performed. CONCLU-SIONS: Anticancer drug expenditure in the outpatient setting has been increasingly growing during the study period. Both the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices) seem to be explanatory factors determining drug spending trends in Catalonia. A more comprehensive approach to the use of anticancer drugs by type of cancer is of high importance.
PCN153 PERFORMANCE MONITORING OF ORGANIZED CANCER SCREENING PROGRAMMES USING ADMINISTRATIVE DATA

PCN154 ANTICANCER DRUG EXPENDITURE IN
PCN155 "PATIENT ACCESS SCHEMES"-THE USE OF RISK-SHARING IN THE UK
Carroll SM 1 , Wasiak R 2 1 United BioSource Corporation (UBC), London, London, UK, 2 United BioSource-Europe, London, UK OBJECTIVES: To analyse key differences between the recently negotiated Pharmaceutical Price Regulation Scheme (PPRS) and previous schemes. Understanding the implications of these changes is important for the pharmaceutical industry and pricing and reimbursement (P&R) activities, particularly when considering the application of risk-sharing. METHODS: The new and old versions of the PPRS were compared across several dimensions: 1) price cuts; 2) price and profit controls; 3) new initiatives; and 4) incentives. In particular, the recent introduction of "patient access schemes" (PASs) was examined. Recent risk-sharing agreements (Velcade and Lucentis) were presented as case studies. To provide an international perspective and cross-market comparison, the analysis also considered examples of risk-sharing schemes as used in
